Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Cash & Equivalents (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Cash & Equivalents for 4 consecutive years, with $61.9 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 5.84% to $61.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.9 million through Dec 2025, up 5.84% year-over-year, with the annual reading at $61.9 million for FY2025, 5.84% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $61.9 million at Century Therapeutics, down from $127.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $260.4 million in Q2 2024, with the low at $46.8 million in Q1 2024.
  • Average Cash & Equivalents over 4 years is $106.8 million, with a median of $85.5 million recorded in 2022.
  • Peak annual rise in Cash & Equivalents hit 304.03% in 2024, while the deepest fall reached 77.24% in 2024.
  • Over 4 years, Cash & Equivalents stood at $84.3 million in 2022, then surged by 204.72% to $256.8 million in 2023, then crashed by 77.24% to $58.4 million in 2024, then rose by 5.84% to $61.9 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $61.9 million, $127.0 million, and $152.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.